Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diosmectite + loperamide
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Diosmectite + loperamide is a combination therapy used for the treatment of acute and chronic diarrhea. Diosmectite is a natural aluminomagnesium silicate clay with strong adsorbent properties, which acts by binding bacteria, bacterial toxins, viruses, and other substances in the gut. It also reduces inflammation and modifies mucus properties to protect the intestinal lining[2][4][8]. Loperamide is an antidiarrheal agent that acts as a mu-opioid receptor agonist in the gut to slow intestinal motility and reduce fluid secretion, thereby decreasing stool frequency and improving stool consistency[1][3][5]. The combination targets both symptomatic relief through reduced motility (loperamide) and protection/adsorption of irritants in the intestine (diosmectite). Both agents are well established for use in diarrhea management.
- Brand names
- Smecta (for diosmectite)Smecdral (for diosmectite)Imodium (for loperamide)Diamode (for loperamide)Pepto Diarrhea Control (for loperamide)
- Other names
- diosmectite + loperamidemontmorillonite + loperamide
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on diosmectite + loperamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diosmectite + loperamide.